Breakthrough killed whole-cell vaccine shows promise against Chlamydia infections

Researchers at the Uniformed Services University (USU) have developed a killed, whole-cell vaccine that demonstrates high efficacy against chlamydia infections. This groundbreaking work, led by Drs. George Liechti, Ann Jerse, and Michael Daly from USU, alongside Dr. Andrew Macintyre from Duke University, was published in npj Vaccines. The study highlights the vaccine’s ability to provide protective effects in mice, enabling rapid clearance of infections and significantly reducing infectious burdens compared to unimmunized controls. These findings reignite the long-standing debate about the potential of killed whole-cell vaccines in preventing chlamydia infections. Chlamydia remains a critical public health challenge. In 2022, the CDC reported over 1.6 million cases, with young women aged 15–24 disproportionately affected. Left untreated, infections can lead to severe complications, including pelvic inflammatory disease (PID), ectopic pregnancies, and infertility. Globally, chlamydia is also the leading cause of infectious blindness (trachoma), with over 40 million people currently affected, according to the...